U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330531) titled 'Drug-drug Interaction Study of Rifampin and Anaprazole Sodium' on Dec. 19, 2025.
Brief Summary: A drug-drug interaction study designed to evaluate the drug-drug interaction between rifampin capsules and anaprazole sodium enteric-coated tablets in healthy adult subjects
Study Start Date: Jan. 04
Study Type: INTERVENTIONAL
Condition:
Drug-drug Interaction Study
Intervention:
DRUG: Anelazol Sodium Enteric-coated Tablets
60mg QD
DRUG: Rifampicin Capsules
600mg QD
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Diges...